Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome

Randomization of patient with pes anserinus bursitis at opd od ramathibodi hospital.

Objective : to study the efficacy of treatment between PRP injection and corticosteroid injection in patients with pes anserinus bursitis

Medhods :

A randomized controlled trial , Single blinded Participants : Patients with pes anserinus bursitis Randomization : Randomization will be performed using the software STATA 16.0 (StataCorp, College Station, Texas, USA). A various blocked randomization method

Interventions and control :

• Experimental groups : PRP injection 4 ml
• Control groups : Steroid injection , Triamcinolone acetonide(40mg/ml) 1 ml + 1%Lidocaine without adrenaline 3 ml = 4ml By Orthopedic surgeon with ultrasound guide.

Allocation and concealment :

A central randomization service will prepare sealed envelopes containing the assigned treatment for each patient.

The envelopes will be kept in secure location until Break the concealment at outpatient orthopedics department , Ramathibodi hospital

Blinding :

Randomized controlled trial study, Single blinded The assessor who will be follow up the patients, will be blinded to the group assignments.

Outcome measures:

Visual Analogue Scale (VAS) , Womac scores

Follow up:

at 4 weeks, 12 weeks, and 24 weeks after injection.

Statistic analysis:

STATA 16.0, StataCorp, College Station, Texas, USA Analysis Demographic data : mean, SD Mean difference in patient-relevant outcomes : Independent T- test

Inclusion criteria

• Over 18 years old
• Patients diagnosed with Pes Anserine Pain Syndrome
• Patients willing to participate in the research project by signing a consent form

Exclusion criteria

• Patients with a localized knee infection or a disseminated infection within the past 3 months
• Patients with thyroid disorders, rheumatoid arthritis, or other types of knee arthritis
• Patients with abnormal blood coagulation or thrombocytopenia
• Patients who are pregnant
• Patients with any type of cancer
• Patients who cannot follow up with treatment until the end of the project
• Patients who are unwilling to participate in the project or wish to withdraw from the research project